Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 14,040 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $13.93, for a total value of $195,577.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Kenneth Hoberman also recently made the following trade(s):
- On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total value of $169,351.74.
- On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total value of $169,918.94.
Shares of Stemline Therapeutics Inc (NASDAQ:STML) traded up $0.25 on Friday, hitting $14.10. The stock had a trading volume of 100,595 shares, compared to its average volume of 208,878. Stemline Therapeutics Inc has a 12-month low of $5.50 and a 12-month high of $16.20. The company has a market capitalization of $352.75, a PE ratio of -5.49 and a beta of -0.02.
A number of brokerages recently issued reports on STML. BidaskClub cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. ValuEngine upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 14th. Finally, Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $33.75.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.